Provided by Tiger Trade Technology Pte. Ltd.

Lucid Group Inc

2.50
-0.2900-10.39%
Post-market: 2.590.0900+3.60%19:59 EST
Volume:15.55M
Turnover:40.42M
Market Cap:990.63M
PE:-0.19
High:2.81
Open:2.74
Low:2.49
Close:2.79
52wk High:14.26
52wk Low:2.37
Shares:396.25M
Float Shares:159.18M
Volume Ratio:1.19
T/O Rate:9.77%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-13.0020
EPS(LYR):-11.8124
ROE:-155.08%
ROA:-29.47%
PB:-0.47
PE(LYR):-0.21

Loading ...

Can Lucid Group (LCID) Justify Its Valuation After Higher Sales And A Narrower Loss?

Simply Wall St.
·
Yesterday

AIB Data Centers price target lowered to $2 from $6.75 at Lucid Capital

TIPRANKS
·
Nov 18

Pulmonx initiated with a Buy at Lucid Capital

TIPRANKS
·
Nov 18

Cue selloff brings ‘attractive buying opportunity,’ says Lucid Capital

TIPRANKS
·
Nov 18

SS Innovations price target lowered to $2 from $7 at Lucid Capital

TIPRANKS
·
Nov 18

Sales Growth And Narrower Loss Could Be A Game Changer For Lucid Stock (LCID)

Simply Wall St.
·
Nov 18

Pearl Diver Credit price target lowered to $9 from $11 at Lucid Capital

TIPRANKS
·
Nov 17

AirJoule Technologies price target lowered to $6 from $10 at Lucid Capital

TIPRANKS
·
Nov 17

Lucid ups Helus target, sees selloff as ‘significant misunderstanding’

TIPRANKS
·
Nov 17

Quantum BioPharma (NASDAQ: QNTM) Reports $12.22M in Cash and Digital Assets, Advances Lucid-MS Phase 2 Trial

TIPRANKS
·
Nov 17

What Has Changed For Lucid Group Since Its 77% Fall

Simply Wall St.
·
Nov 16

Eagle Point Credit price target lowered to $4 from $5 at Lucid Capital

TIPRANKS
·
Nov 16

Sound Point price target lowered to $9 from $11 at Lucid Capital

TIPRANKS
·
Nov 16

Lucid Diagnostics Earnings Call Signals Medicare Growth

TIPRANKS
·
Nov 15

Lucid Group (LCID) Could Be 2% Below Fair Value After Q3 2026 Earnings

Simply Wall St.
·
Nov 14

Lucid Grants Chief Accounting Officer Neil James Laverty 303,327 Performance-Based Stock Units

Reuters
·
Nov 14

Lucid Group Files Initial Beneficial Ownership Statement for Chief Accounting Officer Neil James Laverty

Reuters
·
Nov 14

Lucid Diagnostics (LUCD) Receives a Buy from Maxim Group

TIPRANKS
·
Nov 14

Press Release: PAVmed Provides Business Update and Reports Preliminary Third Quarter 2026 Financial Results

Dow Jones
·
Nov 13

Press Release: Quantum BioPharma Achieve 91% Increase in Shareholder Equity and Liquidity in Q3 2026 as Lucid-MS Phase 2 Trial Advances into Study Start-up

Dow Jones
·
Nov 13